Alaunos Therapeutics Files 2023 Annual Report on Form 10-K

TL;DR

<b>Alaunos Therapeutics (TCRT) has filed its 2023 10-K report, detailing its operations and financial status for the fiscal year ending December 31, 2023.</b>

AI Summary

Alaunos Therapeutics, Inc. (TCRT) filed a Annual Report (10-K) with the SEC on April 1, 2024. Alaunos Therapeutics, Inc. (TCRT) filed its 2023 Form 10-K on April 1, 2024. The company was formerly known as ZIOPHARM ONCOLOGY INC and EASYWEB INC. The filing covers the fiscal year ending December 31, 2023. Key agreements mentioned include those with The University of Texas MD Anderson Cancer Center and The Texas A&M University System. The company's business address is in Houston, TX.

Why It Matters

For investors and stakeholders tracking Alaunos Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Alaunos Therapeutics' financial health, operational activities, and strategic partnerships for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The report details various agreements and historical company name changes, offering context on the company's evolution and its ongoing collaborations, particularly with major research institutions like MD Anderson.

Risk Assessment

Risk Level: medium — Alaunos Therapeutics, Inc. shows moderate risk based on this filing. The company's financial performance and operational status are detailed in this 10-K, but specific financial figures like revenue, net income, or debt levels are not provided in the initial header information, requiring a deeper dive into the document for a full assessment.

Analyst Insight

Review the full 10-K filing for detailed financial statements, risk factors, and management discussion to understand Alaunos Therapeutics' current financial health and strategic direction.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-04-01 — Filing Date (Date of submission)
• 1934 Act — SEC Act (Legislation governing the filing)
• 001-33038 — SEC File Number (Company's SEC file number)

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — Filer name
• TCRT (company) — Ticker symbol
• ZIOPHARM ONCOLOGY INC (company) — Former company name
• EASYWEB INC (company) — Former company name
• The University of Texas MD Anderson Cancer Center (company) — Partner in agreements
• The Texas A&M University System (company) — Partner in agreements
• Houston, TX (location) — Business address

FAQ

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-04-01: Filing Date — Date the 10-K was officially submitted to the SEC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the official annual financial and operational overview for Alaunos Therapeutics.)

SEC

U.S. Securities and Exchange Commission, an independent agency of the U.S. federal government responsible for enforcing federal securities laws, pushing disclosure of market details, and protecting investors. (The SEC mandates the filing of this 10-K report.)

Key Financial Figures

• $7.65 — y non-affiliates and a closing price of $7.65 as reported on the Nasdaq Capital Marke
• $0.001 — hares of the registrant's common stock, $0.001 par value per share, outstanding. 1

Filing Documents

• tcrt-20231231.htm (10-K) — 2262KB
• tcrt-ex10_59.htm (EX-10.59) — 47KB
• tcrt-ex10_60.htm (EX-10.60) — 84KB
• tcrt-ex10_61.htm (EX-10.61) — 49KB
• tcrt-ex10_62.htm (EX-10.62) — 76KB
• tcrt-ex23_1.htm (EX-23.1) — 4KB
• tcrt-ex31_1.htm (EX-31.1) — 13KB
• tcrt-ex32_1.htm (EX-32.1) — 7KB
• tcrt-ex97_1.htm (EX-97.1) — 37KB
• img160836378_0.jpg (GRAPHIC) — 15KB
• img160836378_1.jpg (GRAPHIC) — 42KB
• img160836378_2.jpg (GRAPHIC) — 353KB
• 0000950170-24-038868.txt (&nbsp;) — 10213KB
• tcrt-20231231.xsd (EX-101.SCH) — 1487KB
• tcrt-20231231_htm.xml (XML) — 1235KB

Business

Business 7 Item 1A.

Risk Factors

Risk Factors 27 Item 1B. Unresolved Staff Comments 52 Item IC. Cybersecurity 53 Item 2.

Properties

Properties 53 Item 3.

Legal Proceedings

Legal Proceedings 53 Item 4. Mine Safety Disclosures 54 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 55 Item 6. [Reserved] 55 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 56 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 65 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 66 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures 66 Item 9A.

Controls and Procedures

Controls and Procedures 66 Item 9B. Other Information 67 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 67 PART III Item 10. Directors, Executive Officers and Corporate Governance 68 Item 11.

Executive Compensation

Executive Compensation 68 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 68 Item 13. Certain Relationships and Related Transactions, and Director Independence 68 Item 14. Principal Accountant Fees and Services 68 PART IV Item 15. Exhibits and Financial Statement Schedules 69 Item 16. Form 10-K Summary 72

Financial Statements

Financial Statements F- 1 3 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Annual Report that are not historical fact, and in some cases can be identified by terms such as: "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "target," "potential," "will" and other words and terms of similar meaning. These statements are based on management's current beliefs and assumptions and on information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this Annual Report include, but are not limited to, statements about: our ability to successfully implement our strategic reprioritization or realize any or all of the anticipated benefits once implemented; our ability to raise substantial additional capital to continue as a going concern and fund our planned operations in the near term and our strategic reprioritization in the longer term; our ability to successfully consummate any strategic transactions, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions; estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirem

Business

Item 1. Business Overview We are a clinical-stage oncology-focused cell therapy company that was historically involved in developing adoptive T-cell receptor, or TCR, engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We leveraged our cancer hotspot mutation TCR library and our proprietary, non-viral Sleeping Beauty gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including KRAS , TP53 and EGFR . In collaboration with The University of Texas MD Anderson Cancer Center, or MD Anderson, we were enrolling and treating patients for a Phase 1/2 clinical trial evaluating 12 TCRs reactive to mutated KRAS , TP53 and EGFR from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial. On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has reduced its workforce by approximately 95% to date and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald & Co., or Cantor, to act as strategic advisor for this process. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology. In addition, on August 14, 2023, we announced that we had provided the requisite notice to the National Cancer Institute, or NCI, to terminate the Cooperative Research and Development Agreement, dated

View Full Filing

View this 10-K filing on SEC EDGAR